BIRC5 and hepatocellular carcinoma: Although FTS had no effect on the activity of both capase-8 and -9, it significantly increased the DHA/ARS-induced caspase-8 and -9 activations (Fig 4A and 4B), similar to the action of the combination treatment of TRAIL and FTS in HCC cells, in which FTS increased death reporter (DR) 5 expression and inhibited survivin expression to increase the caspase-8 and -9 activations level induced by TRAIL in HCC cells [35].